Bromide

Bromide

SCHEMBL284742

CN(C)c1ccc(C=Cc2cc[n+](CCCCCC(=O)O)cc2)cc1.[Br-]

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHKA known ✓ P35790 2/20 0.54
CHRM2 known ✓ P08172 2/20 0.44
CHRM4 known ✓ P08173 2/20 0.44
CHRM5 known ✓ P08912 2/20 0.44
CHRM1 known ✓ P11229 2/20 0.44
CHRM3 known ✓ P20309 2/20 0.44
KDM4A O75164 6/20 0.67
KDM2A Q9Y2K7 6/20 0.67
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
CASP1 P29466 1/20 0.47
BRCA1 P38398 1/20 0.47
CASP7 P55210 1/20 0.47
HBB P68871 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
ALPG P10696 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL285125 1.00 KDM4A (0.67) KDM4AKDM2ACHKAMEN1MAPT
SCHEMBL9882784 0.93 KDM4A (0.63) KDM4AKDM2ACHKAMEN1MAPT
Bromide SCHEMBL17221057 0.89 KDM4A (0.57) KDM4AKDM2ACHKAMEN1MAPT
Bromide SCHEMBL17221056 0.89 KDM4A (0.57) KDM4AKDM2ACHKAMEN1MAPT
SCHEMBL15797224 0.88 KDM4A (0.58) KDM4AKDM2AMEN1MAPTKMT2A
SCHEMBL15797226 0.88 KDM4A (0.58) KDM4AKDM2AMEN1MAPTKMT2A
SCHEMBL12533259 0.86 KDM4A (0.88) KDM4AKDM2ACHKAMEN1MAPT
SCHEMBL13645407 0.84 KDM4A (0.84) KDM4AKDM2ACHKAMEN1MAPT
SCHEMBL13205953 0.83 KDM4A (0.64) KDM4AKDM2ACHKAMEN1MAPT
Bromide SCHEMBL313907 0.82 KDM4A (0.97) KDM4AKDM2ACHKAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580749-B2 Dyes and labeled molecules BIOTIUM, INC. (US) 2017-02-28 US disclosed
US-9102835-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2015-08-11 US disclosed
US-8753814-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2014-06-17 US disclosed
US-20140106349-A1 Dyes and Labeled Molecules ALLELOGIC BIOSCIENCES CORPORATION (US) 2014-04-17 US disclosed
US-20140073058-A1 Methods of Using Dyes in Association with Nucleic Acid Staining or Detection and Associated Technology BIOTIUM, INC. (US) 2014-03-13 US disclosed
US-8530195-B2 Dyes and labeled molecules BIOTIUM, INC. (US) 2013-09-10 US disclosed
US-20130167309-A1 METHODS OF USING DYES IN ASSOCIATION WITH NUCLEIC ACID STAINING OR DETECTION AND ASSOCIATED TECHNOLOGY BIOTIUM, INC. (US) 2013-07-04 US disclosed
EP-2428586-B1 Dimeric nucleic acid dyes, and associated systems and methods BIOTIUM INC (US) 2013-05-08 EP disclosed
US-8232050-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2012-07-31 US disclosed
EP-2428586-A1 Dimeric and trimeric nucleic acid dyes, and associated systems and methods Biotium Inc. (US) 2012-03-14 EP disclosed
US-20100317016-A1 DYES AND LABELED MOLECULES BIOTIUM, INC. (US) 2010-12-16 US disclosed
US-7803943-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2010-09-28 US disclosed
US-7776567-B2 Dimeric and trimeric nucleic acid dyes, and associated systems and methods BIOTIUM, INC. (US) 2010-08-17 US disclosed
US-20100009454-A1 METHODS OF USING DYES IN ASSOCIATION WITH NUCLEIC ACID STAINING OR DETECTION AND ASSOCIATED TECHNOLOGY BIOTIUM, INC. 2010-01-14 US disclosed
US-7601498-B2 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. (US) 2009-10-13 US disclosed
EP-1863933-A4 DIMERIC AND TRIMERIC NUCLEIC ACID DYES, AND ASSOCIATED SYSTEMS AND METHODS BIOTIUM INC (US) 2009-04-08 EP disclosed
EP-1863933-A2 DIMERIC AND TRIMERIC NUCLEIC ACID DYES, AND ASSOCIATED SYSTEMS AND METHODS Biotium Inc. (US) 2007-12-12 EP disclosed
WO-2006099605-A2 DIMERIC AND TRIMERIC NUCLEIC ACID DYES, AND ASSOCIATED SYSTEMS AND METHODS BIOTIUM, INC. (US) 2006-09-21 WO disclosed
US-20060211029-A1 Methods of using dyes in association with nucleic acid staining or detection and associated technology BIOTIUM, INC. 2006-09-21 US disclosed
US-20060211028-A1 Dimeric and trimeric nucleic acid dyes, and associated systems and methods ALLELOGIC BIOSCIENCES CORPORATION 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317016-A1 DYES AND LABELED MOLECULES DNA2, POLL, POLRMT CHKA 3186/4885CHRM2 4872/4885CHRM4 4842/4885
US-20060211028-A1 Dimeric and trimeric nucleic acid dyes, and associated systems and methods DNA2, POLRMT, POLL CHKA 3705/4885CHRM2 4883/4885CHRM4 4874/4885
US-20060211029-A1 Methods of using dyes in association with nucleic acid staining or detection and associated technology HNRNPLL, HNRNPL, HNRNPH3 CHKA 3177/4885CHRM2 4824/4885CHRM4 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.